EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who treated with platin-based adjuvant chemotherapy

Mehmet Ünsal iD, Meltem Yücesoy iD, Okan Oktar iD, Yeşim Uçar iD, Gülşah Tiryaki Güner iD, Okan Aytekin iD, A Alp Tokalioğlu iD, Hande Esra Koca Yildirim iD, Fatih Kiliç iD, Burak Ersak iD, Caner Çakir iD, Dilek Yüksel iD und 6 weitere

Turkish Journal of Medical Sciences · 17.04.2025 · 55 (2) · 368-376

DOI: 10.55730/1300-0144.5980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 17.04.2025. Verfasst von Mehmet Ünsal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ank…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Epithelial ovarian cancer is the second most prevalent type of gynecological cancer. We aimed to investigate prognostic factors related to survival in patient with 2014 FIGO stage IIIC high-grade serous ovarian cancer (HGSOC). Materials and methods: Two hundred fifty eight patients were evaluated retrospectively. The absence of a visible tumor was determined as maximum cytoreduction, and a residual tumor size of 1 cm or less was determined as optimal cytoreduction. Patients who underwent cytoreduction followed by a combination of platinum and taxane adjuvant chemotherapy were included. Exclusion criteria for the study were patients taking neoadjuvant chemotherapy and those with suboptimal surgery.

Results

Optimal cytoreduction was performed in 107 and maximal cytoreduction was performed in 151 patients. The five-year PFS rate was 27% and the five-year DSS rate was 76%. While high ascites volume and optimal cytoreduction were identified as independent prognostic factors for disease failure, only optimal cytoreduction was an independent prognostic factor for survival.

Conclusion

The maximal cytoreduction is improves PFS and DSS in patients with 2014 FIGO stage IIIC HGSOC as our study results. Therefore, maximum surgical effort and radical cytoreductive procedures should be performed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousHumansFemaleChemotherapy, AdjuvantMiddle AgedRetrospective StudiesAgedNeoplasm StagingAdultCytoreduction Surgical ProceduresPrognosisAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Stage IIICcytoreductionhigh-grade serous ovarian cancersurvival

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Ankara City Hospital, Ankara, Turkiye.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Health Sciences University, Etlik Zübeyde Hanim Women's Health Training and Research Hospital, Ankara, Turkiye.

ORCID-Profile: Mehmet Ünsal, Meltem Yücesoy, Okan Oktar, Yeşim Uçar, Gülşah Tiryaki Güner, Okan Aytekin, A Alp Tokalioğlu, Hande Esra Koca Yildirim, Fatih Kiliç, Burak Ersak, Caner Çakir, Dilek Yüksel, Çiğdem Kiliç, Sevgi Koç, Günsu Kimyon Cömert, Özlem Moraloğlu Tekin, Yaprak Engin Üstün, Taner Turan

Zitieren

APA

Ünsal, M., Yücesoy, M., Oktar, O., Uçar, Y., Güner, G. T., Aytekin, O., Tokalioğlu, A. A., Yildirim, H. E. K., Kiliç, F., Ersak, B., Çakir, C., Yüksel, D., Kiliç, Ç., Koç, S., Cömert, G. K., Tekin, Ö. M., Üstün, Y. E., & Turan, T. (2025). Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who treated with platin-based adjuvant chemotherapy. Turkish Journal of Medical Sciences, 55(2), 368-376. https://doi.org/10.55730/1300-0144.5980

Vancouver

Ünsal M, Yücesoy M, Oktar O, Uçar Y, Güner GT, Aytekin O, et al. Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who treated with platin-based adjuvant chemotherapy. Turkish Journal of Medical Sciences. 2025;55(2):368-376. doi:10.55730/1300-0144.5980

BibTeX
@article{nsal2025,
  author = {Ünsal, Mehmet and Yücesoy, Meltem and Oktar, Okan and Uçar, Yeşim and Güner, Gülşah Tiryaki and Aytekin, Okan and Tokalioğlu, A Alp and Yildirim, Hande Esra Koca and Kiliç, Fatih and Ersak, Burak and Çakir, Caner and Yüksel, Dilek and Kiliç, Çiğdem and Koç, Sevgi and Cömert, Günsu Kimyon and Tekin, Özlem Moraloğlu and Üstün, Yaprak Engin and Turan, Taner},
  title = {Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who treated with platin-based adjuvant chemotherapy},
  journal = {Turkish Journal of Medical Sciences},
  year = {2025},
  volume = {55},
  number = {2},
  pages = {368--376},
  doi = {10.55730/1300-0144.5980}
}
Kostenlos starten →